Integra LifeSciences Q3 revenue $402.1M, adjusted EPS $0.54; cuts full-year guidance

INTEGRA LIFESCIENCES HOLDINGS CORP

2025-Q3 EPS reported -$6.72 revenue$1,200,320,000

Q3 reported revenues $402.1M, +5.6% YoY; organic growth 5.0%.
GAAP net loss $(5.4)M ($(0.07)/diluted share); adjusted EPS $0.54 vs $0.41 YoY.
Codman Specialty Surgical revenues $292.6M (+8.1% reported); Tissue Technologies $109.5M (-0.5% reported).
Full-year 2025 revenue guidance cut to $1.620B-$1.640B (organic growth -1.6% to -0.4%); adj EPS $2.19-$2.24.
Relaunched PriMatrix and Durepair ahead of schedule; Braintree facility on track for production in June 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.